Cara Therapeutics, Inc. (Nasdaq: CARA) today announced statistically significant topline results from its Phase 2 trial of its lead kappa ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE